Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer

Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer

Background: Rearranged during transfection (RET) gene fusion is a target for non-small cell lung cancer (NSCLC) treatment, and RET inhibitors are approved for advanced NSCLC. The role of immune checkpoint inhibitors (ICIs) in RET fusion-positive NSCLC remains controversial. This retrospective study...

Full description

Bibliographic Details
Main Authors: Rui Wan, Weihua Li, Zhijie Wang, Jia Zhong, Lin Lin, Jianchun Duan, Jie Wang
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Heliyon
Subjects:
RET fusion
Lung cancer
Immunotherapy
Targeted therapy
RET inhibitors
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024008272

Internet

http://www.sciencedirect.com/science/article/pii/S2405844024008272

Similar Items